Research Report: Injective (INJ) Reverse Due
Published 4/9/2026, 7:35:04 AM
To: Investment Committee
From: Senior Director of Research
Date: April 9, 2026
Subject: INJ Post-Halving Performance and Competitive Positioning
Executive Summary
Injective (INJ) has entered a mature, deflationary phase following the IIP-617 upgrade, with 99.97% of its 100 million supply now circulating [Source: https://coinlaw.io/injective-statistics/]. While technical infrastructure (640ms block times) and institutional RWA adoption (e.g., Pineapple Financial’s $10B migration) are robust, the protocol faces a significant "valuation-to-revenue" gap compared to Hyperliquid, which dominated 2025 volumes [Source: https://blockeden.xyz/blog/2026/01/10/hyperliquid-revenue-dominance-onchain-trading-solana/].
1. Current Situation and Risk Assessment
- Inflation & Unlocks: The "aggressive deflation phase" initiated by IIP-617 in early 2026 has effectively neutralized previous concerns regarding supply expansion. With nearly the entire supply unlocked, the primary selling pressure is no longer venture-capital cliffs but rather organic staking outflows [Source: https://cryptorank.io/news/feed/e4300-injective-passes-vote-to-cut-inj-supply-and-boost-deflation].
- Technical Utility: The 1.4-second marketing TPS is superseded by a real-world capacity of 25,000+ TPS and 640ms block times [Source: https://coinlaw.io/injective-statistics/]. This sub-second finality is the backbone of its on-chain order book, though its utility is currently concentrated in high-frequency derivatives rather than general retail dApps.
- Cosmos Integration:
- Pros: Native IBC interoperability allows Injective to act as a liquidity hub for 23+ chains.
- Cons: The "liquidity silo" risk remains as Ethereum L2s capture the bulk of retail stablecoin volume.
2. Short-Term Catalysts (1-3 Months)
The immediate horizon is dominated by the MultiVM mainnet rollout, which introduces SVM (Solana) and EVM (Ethereum) compatibility to the Injective environment [Source: https://coinlaw.io/injective-statistics/].
Sensitivity Ratings (Scale 1-10):
| Factor | Rating | Rationale |
|---|---|---|
| BTC Price Movements | 8/10 | High correlation persists despite deflationary burns. |
| Fed Policies | 7/10 | Finance-centric chain; sensitive to macro liquidity and yield spreads. |
| Regulatory Shifts | 6/10 | Impacted by SEC decisions on pending spot INJ ETFs [Source: https://coinlaw.io/injective-statistics/]. |
- ETF Expectations: Both Canary Capital and 21Shares have filed for spot INJ ETFs as of late 2025, providing a massive potential liquidity bridge for institutional capital [Source: https://coinlaw.io/injective-statistics/].
3. Mid-Term Scenario Analysis (3-6 Months)
Injective is currently in a "squeeze" between the professional-grade dYdX and the high-growth Hyperliquid.
| Scenario | Probability | Key Verification Indicator |
|---|---|---|
| Ecosystem Explosion | 20% | Spot ETF approval + RWA TVL exceeding $20B. |
| Steady Follow-up | 60% | MultiVM adoption leads to consistent $500M+ daily volume. |
| Marginalization | 20% | Hyperliquid captures >90% of decentralized perpetual volume. |
Competitor Context: Hyperliquid closed 2025 with $2.95 trillion in volume and $844 million in revenue, setting a high bar for Injective’s fee-capture model [Source: https://blockeden.xyz/blog/2026/01/10/hyperliquid-revenue-dominance-onchain-trading-solana/].
4. On-Chain Alerts & Intelligence
- Smart Money: Revolut has emerged as a major holder, recently withdrawing 380,000 INJ (~$11M) from Coinbase, bringing its total treasury to 883,689 INJ (~$262M) [Source: https://x.com/FurkanConsensus/status/2041929331467747537].
- DEX Resilience: The native DEX, Helix, has processed $76.2 billion in cumulative volume [Source: https://x.com/injective/status/2040797189929111799]. While resilient, 24h chain fees remain modest at approximately $8,900 [Source: https://coinlaw.io/injective-statistics/].
- Staking Trends: Over 57 million INJ are currently staked. The 21-day unstaking queue shows no signs of a mass exit, suggesting high conviction among long-term validators like Google Cloud and Deutsche Telekom [Source: https://x.com/injective/status/2041524655731732715].
5. Valuation De-watering
A critical disconnect exists between Injective's institutional adoption and its protocol revenue.
- Institutional Progress: Injective is leading in RWA deployment, evidenced by Pineapple Financial’s $10B mortgage migration completed in December 2025 [Source: https://coinmarketcap.com/cmc-ai/injective/price-prediction/].
- Revenue Comparison:
- Injective: 24h fees ~$8,900; FDV estimates vary widely but institutional holdings suggest a multi-billion dollar market cap [Source: https://coinlaw.io/injective-statistics/].
- Hyperliquid: $844M annual revenue (2025) [Source: https://blockeden.xyz/blog/2026/01/10/hyperliquid-revenue-dominance-onchain-trading-solana/].
Conclusion
Injective is a technically superior "financial dedicated chain" with elite institutional backing, but it is currently over-valued on a price-to-sales (P/S) basis when compared to Hyperliquid. The short-term bull case relies entirely on ETF approvals and the MultiVM rollout to bridge the revenue gap. We recommend monitoring the $10B Pineapple Financial RWA utilization rates as the primary KPI for mid-term valuation support.
Open Question: Will the MultiVM rollout successfully attract Solana-based liquidity, or will Hyperliquid's vertical integration continue to dominate the derivatives market share?